Remission of metastatic duodenal cancer after treatment with BRAF inhibitor

Ugeskrift for Læger 2026 Open access

Read full text
Authors: Helene Benedikte Hansen, Julia Johanna Almer Bromann, Dan Høgdall, Jakob Vasehus Schou, Rikke Løvendahl Eefsen
DOI: 10.61409/v08250650
Cited by: 0
References: 4

Abstract

Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. This case report describes a patient with metastatic duodenal cancer with a BRAF V600E mutation who achieved durable complete remission following this treatment. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the importance of molecular profiling in rare cancers. Further research is needed on the effect and safety of targeted therapy for small bowel adenocarcinoma.

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Gastrointestinal Tumor Research and Treatment Pancreatic and Hepatic Oncology Research

Publication details

Journal / source
Ugeskrift for Læger
Volume
188
Issue
5
Pages
1–3
Publication date
26 January 2026
Language
DA